Avantgen Inc.
San Diego, CA
- UEI
- WLNHKNPNT2M7
- CAGE
- 4NTY2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6162 Nancy Ridge Dr #150, San Diego, CA 92121, USA
- Website
- avantgen.com
- Founded
- 2006
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,497,384 |
| FY2024 | $592,751 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Avantgen Inc. is a San Diego-based biotechnology company registered in the System for Award Management (SAM) since 2007, specializing in the development of advanced diagnostic technologies, monoclonal antibodies, and innovative therapeutic research. The company primarily serves federal agencies in the biomedical and infectious disease research sectors, with a focused expertise in developing rapid diagnostic test kits, therapeutic reagents, and specialized biomedical research tools. Through its federal contract and grant work, Avantgen demonstrates a strong capability in creating cutting-edge biotechnology solutions for complex medical and research challenges.
Avantgen has been awarded multiple federal contracts, predominantly from the National Institutes of Health (NIH) agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Biomedical Imaging and Bioengineering. These contracts, which range from $300,000 to $3.75 million, have focused on developing rabbit monoclonal antibodies for various biomarkers, including ferret and bat virus research, and creating rapid diagnostic test kits for infectious diseases like SARS-CoV-2 and hepatitis C. Several contracts were set aside for small businesses, and the company has collaborated with subcontractors like Nanocomposix, Inc. and Duke University to expand its research capabilities and technical expertise.
The company has also received federal grant awards, most notably a $1,398,552 Project Grant from the National Cancer Institute to conduct preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This research aims to develop innovative therapeutic approaches for blood cancers, focusing on creating an antibody that can disrupt critical oncogenic pathways in leukemic stem cells. The grant supports advanced preclinical research, including cell line development, early chemistry, manufacturing and controls (CMC) work, and preliminary toxicology studies on a lead antibody candidate designed to inhibit leukemic blast proliferation and induce apoptosis.
Quick answers
Is Avantgen Inc. registered in SAM.gov?
Yes. Avantgen Inc.'s SAM.gov registration is active through November 5, 2026.
How much has Avantgen Inc. received in federal contracts?
Federal contracts obligated $1,497,384 to Avantgen Inc. in fiscal year 2025 and $2,090,135 in fiscal years 2023 through 2027.
What is Avantgen Inc.'s most recent federal award?
Avantgen Inc.'s most recent federal contract award is Development of rabbit monoclonal antibodies for ferret biomarkers (75N93025C00013), from National Institute of Allergy and Infectious Diseases (NIH), on February 1, 2025.
On GovTribe
See Avantgen Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors